Top

Published in:

Open Access 01-12-2012 | Review

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients

Authors: Sandeep S Patil, Ivaylo Gentschev, Ingo Nolte, Gregory Ogilvie, Aladar A Szalay

Published in: Journal of Translational Medicine | Issue 1/2012

Abstract

Oncolytic viruses refer to those that are able to eliminate malignancies by direct targeting and lysis of cancer cells, leaving non-cancerous tissues unharmed. Several oncolytic viruses including adenovirus strains, canine distemper virus and vaccinia virus strains have been used for canine cancer therapy in preclinical studies. However, in contrast to human studies, clinical trials with oncolytic viruses for canine cancer patients have not been reported. An 'ideal' virus has yet to be identified. This review is focused on the prospective use of oncolytic viruses in the treatment of canine tumors - a knowledge that will undoubtedly contribute to the development of oncolytic viral agents for canine cancer therapy in the future.

Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G, Bocchini V: Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med. 2008, 22: 976-984. 10.1111/j.1939-1676.2008.0133.x.PubMed

National Canine Cancer Foundation. [http://www.earethecure.org/]

Kelsey JL, Moore AS, Glickman LT: Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev. 1998, 20: 204-217.PubMed

Southam CM, Moore AE: Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer. 1952, 5: 1025-1034. 10.1002/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q.PubMed

Sinkovics JG: Viral oncolysates as human tumor vaccines. Int Rev Immunol. 1991, 7: 259-287. 10.3109/08830189109114875.PubMed

Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett. 2007, 254: 178-216. 10.1016/j.canlet.2007.02.002.PubMed

Moore AE: The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer. 1949, 2: 525-534. 10.1002/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O.PubMed

Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ: Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001, 172: 27-36. 10.1016/S0304-3835(01)00617-6.PubMed

Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 2003, 63: 348-353.PubMed

10.

De Palma M, Venneri MA, Naldini L: In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther. 2003, 14: 1193-1206. 10.1089/104303403322168028.PubMed

11.

Fu X, Zhang X: Delivery of herpes simplex virus vectors through liposome formulation. Mol Ther. 2001, 4: 447-453. 10.1006/mthe.2001.0474.PubMed

12.

Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD: Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res. 2004, 10: 53-60. 10.1158/1078-0432.CCR-0690-3.PubMed

13.

Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, Jimenez M, Shamamian P, Jin R, Novick RP, Pellicer A, Meruelo D: Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol. 2004, 22: 70-77. 10.1038/nbt917.PubMed

14.

Vaha-Koskela MJ, Kallio JP, Jansson LC, Heikkila JE, Zakhartchenko VA, Kallajoki MA, Kahari VM, Hinkkanen AE: Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 2006, 66: 7185-7194. 10.1158/0008-5472.CAN-05-2214.PubMed

15.

Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ: Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007, 99: 1623-1633. 10.1093/jnci/djm198.PubMed

16.

Dobbelstein M: Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol. 2004, 273: 291-334.PubMed

17.

Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA: Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007, 67: 10038-10046. 10.1158/0008-5472.CAN-07-0146.PubMed

18.

Lun XQ, Yang WQ, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, John BH, Hamilton MG, Senger DL, Forsyth PA: Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 2005, 65: 9982-9990. 10.1158/0008-5472.CAN-05-1201.PubMedPubMedCentral

19.

Evgin L, Vaha-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM: Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. Molecular Therapy. 2010, 18: 896-902. 10.1038/mt.2010.14.PubMedPubMedCentral

20.

Russell SJ: RNA viruses as virotherapy agents. Cancer Gene Ther. 2002, 9: 961-966. 10.1038/sj.cgt.7700535.PubMed

21.

Parato KA, Senger D, Forsyth PA, Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005, 5: 965-976. 10.1038/nrc1750.PubMed

22.

Cattaneo R, Miest T, Shashkova EV, Barry MA: Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008, 6: 529-540. 10.1038/nrmicro1927.PubMedPubMedCentral

23.

Garber K: China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006, 98: 298-300. 10.1093/jnci/djj111.PubMed

24.

Nemunaitis J, Cunningham C: Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Drug Resist Updat. 2002, 5: 34-46. 10.1016/S1368-7646(02)00048-1.PubMed

25.

Yu W, Fang H: Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007, 7: 141-148. 10.2174/156800907780058817.PubMed

26.

Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996, 274: 373-376. 10.1126/science.274.5286.373.PubMed

27.

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D: Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther. 2005, 12: 1333-1346. 10.1038/sj.gt.3302555.PubMed

28.

Ternovoi VV, Le LP, Belousova N, Smith BF, Siegal GP, Curiel DT: Productive replication of human adenovirus type 5 in canine cells. J Virol. 2005, 79: 1308-1311. 10.1128/JVI.79.2.1308-1311.2005.PubMedPubMedCentral

29.

Smith BF, Curiel DT, Ternovoi VV, Borovjagin AV, Baker HJ, Cox N, Siegal GP: Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother Radiopharm. 2006, 21: 601-606. 10.1089/cbr.2006.21.601.PubMed

30.

Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP, Curiel DT: Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 2006, 13: 389-399. 10.1038/sj.gt.3302674.PubMed

31.

von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Totterman TH: Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother. 2008, 31: 377-384. 10.1097/CJI.0b013e31816a812d.PubMed

32.

International Committee on Taxonomy of Viruses., Van Regenmortel MHV, International Union of Microbiological Societies. Virology Division: Virus taxonomy: classification and nomenclature of viruses: seventh report of the International Committee on Taxonomy of Viruses. 2000, San Diego: Academic Press

33.

Suter SE, Chein MB, von Messling V, Yip B, Cattaneo R, Vernau W, Madewell BR, London CA: In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res. 2005, 11: 1579-1587. 10.1158/1078-0432.CCR-04-1944.PubMed

34.

Bluming AZ, Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971, 2: 105-106.PubMed

35.

Gross S: Measles and leukaemia. Lancet. 1971, 1: 397-398.PubMed

36.

Tatsuo H, Ono N, Tanaka K, Yanagi Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000, 406: 893-897. 10.1038/35022579.PubMed

37.

Tatsuo H, Ono N, Yanagi Y: Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol. 2001, 75: 5842-5850. 10.1128/JVI.75.13.5842-5850.2001.PubMedPubMedCentral

38.

Shchelkunov SN, Totmenin AV, Babkin IV, Safronov PF, Ryazankina OI, Petrov NA, Gutorov VV, Uvarova EA, Mikheev MV, Sisler JR: Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 2001, 509: 66-70. 10.1016/S0014-5793(01)03144-1.PubMed

39.

Moss B, Earl PL: Overview of the vaccinia virus expression system. Curr Protoc Protein Sci. 2001, Chapter 5: Unit5 11

40.

Fenner F: Smallpox and its eradication. World Health Organization, Geneva. 1988

41.

Dranoff G: GM-CSF-based cancer vaccines. Immunol Rev. 2002, 188: 147-154. 10.1034/j.1600-065X.2002.18813.x.PubMed

42.

Clinical Trail Govt Database. [http://clinicaltrialsgov/ct2/show/NCT00794131]

43.

Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9: 533-542. 10.1016/S1470-2045(08)70107-4.PubMed

44.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I: Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J Oncol. 2010, 2010: 736907-PubMedPubMedCentral

45.

Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA: Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther. 2009, 16: 320-328. 10.1038/cgt.2008.87.PubMed

46.

Kelly KJ, Brader P, Woo Y, Li S, Chen N, Yu YA, Szalay AA, Fong Y: Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model. Int J Cancer. 2009, 124: 911-918. 10.1002/ijc.24037.PubMedPubMedCentral

47.

Perkus ME, Taylor J, Tartaglia J, Pincus S, Kauffman EB, Tine JA, Paoletti E: Live attenuated vaccinia and other poxviruses as delivery systems: public health issues. Ann N Y Acad Sci. 1995, 754: 222-233. 10.1111/j.1749-6632.1995.tb44454.x.PubMed

48.

Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P: Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther. 2003, 10: 2126-2132. 10.1038/sj.gt.3302124.PubMed

49.

Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, Canevari S, Hartmann LC, Peng KW: The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res. 2006, 12: 6170-6178. 10.1158/1078-0432.CCR-06-0992.PubMed

50.

Hashiro G, Loh PC, Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977, 54: 307-315. 10.1007/BF01314776.PubMed

51.

Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994, 86: 1228-1233. 10.1093/jnci/86.16.1228.PubMed

52.

Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000, 6: 821-825. 10.1038/77558.PubMed

53.

Yew PR, Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 1992, 357: 82-85. 10.1038/357082a0.PubMed

54.

Zhang J, Chen X, Kent MS, Rodriguez CO: Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor. Mol Cancer Res. 2009, 7: 67-78. 10.1158/1541-7786.MCR-08-0347.PubMedPubMedCentral

55.

Chu LL, Rutteman GR, Kong JM, Ghahremani M, Schmeing M, Misdorp W, van Garderen E, Pelletier J: Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res Treat. 1998, 50: 11-25. 10.1023/A:1006010526813.PubMed

56.

Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I: Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo. 2011, 25: 455-465.PubMed

57.

Levine RA, Fleischli MA: Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol. 2000, 37: 54-61. 10.1354/vp.37-1-54.PubMed

58.

Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Miyoshi N, Hayashi T: Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci. 1999, 61: 27-32. 10.1292/jvms.61.27.PubMed

59.

Carrasco V, Canfran S, Rodriguez-Franco F, Benito A, Sainz A, Rodriguez-Bertos A: Canine gastric carcinoma: immunohistochemical expression of cell cycle proteins (p53, p21, and p16) and heat shock proteins (Hsp27 and Hsp70). Vet Pathol. 2011, 48: 322-329. 10.1177/0300985810375050.PubMed

60.

Kirn DH, Thorne SH: Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009, 9: 64-71. 10.1038/nrc2545.PubMed

61.

Liu L, Chavan R, Feinberg MB: Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008, 9: 15-10.1186/1471-2172-9-15.PubMedPubMedCentral

62.

Thorne SH, Contag CH: Combining immune cell and viral therapy for the treatment of cancer. Cell Mol Life Sci. 2007, 64: 1449-1451. 10.1007/s00018-007-6550-z.PubMed

63.

Nakamura N, Momoi Y, Watari T, Yoshino T, Tsujimoto H, Hasegawa A: Plasma thymidine kinase activity in dogs with lymphoma and leukemia. J Vet Med Sci. 1997, 59: 957-960. 10.1292/jvms.59.957.PubMed

64.

von Euler H, Einarsson R, Olsson U, Lagerstedt AS, Eriksson S: Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004, 18: 696-702.PubMed

65.

Von Euler HP, Rivera P, Aronsson AC, Bengtsson C, Hansson LO, Eriksson SK: Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay. Int J Oncol. 2009, 34: 505-510.PubMed

66.

Selting KA, Thamm DH: Serum thymidine kinase concentrations in normal versus tumor-bearing dogs. Journal of Veterinary Internal Medicine. 2008, 22: 704-704.

67.

Gama A, Gartner F, Alves A, Schmitt F: Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res Vet Sci. 2009, 87: 432-437. 10.1016/j.rvsc.2009.04.016.PubMed

68.

Higgins RJ, Dickinson PJ, LeCouteur RA, Bollen AW, Wang H, Corely LJ, Moore LM, Zang W, Fuller GN: Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J Neurooncol. 2010, 98: 49-55. 10.1007/s11060-009-0072-5.PubMed

69.

Grabarevic Z, Coric M, Seiwerth S, Dzaja P, Artukovic B, Kurilj AG, Beck A, Hohsteter M, Sostaric-Zuckermann IC, Brcic L, Hrstic I: Comparative analysis of hepatocellular carcinoma in men and dogs. Coll Antropol. 2009, 33: 811-814.PubMed

70.

Shiomitsu K, Johnson CL, Malarkey DE, Pruitt AF, Thrall DE: Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Vet Comp Oncol. 2009, 7: 106-114. 10.1111/j.1476-5829.2009.00178.x.PubMed

71.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH: Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 2007, 4: e353-10.1371/journal.pmed.0040353.PubMedPubMedCentral

72.

Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006, 6: 836-848. 10.1038/nri1961.PubMed

73.

Stetson DB, Medzhitov R: Type I interferons in host defense. Immunity. 2006, 25: 373-381. 10.1016/j.immuni.2006.08.007.PubMed

74.

Xu L, Rothman P: IFN-gamma represses epsilon germline transcription and subsequently down-regulates switch recombination to epsilon. Int Immunol. 1994, 6: 515-521. 10.1093/intimm/6.4.515.PubMed

75.

Heise CC, Williams A, Olesch J, Kirn DH: Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 1999, 6: 499-504. 10.1038/sj.cgt.7700071.PubMed

76.

Altomonte J, Marozin S, Schmid RM, Ebert O: Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. 2010, 18: 275-284. 10.1038/mt.2009.231.PubMedPubMedCentral

77.

Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC, Grandi P: Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 2010, 17: 1200-1205. 10.1038/gt.2010.66.PubMedPubMedCentral

78.

Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, Yun CO, Jooss K: Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007, 67: 4399-4407. 10.1158/0008-5472.CAN-06-4260.PubMed

79.

Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R: Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 2010, 18: 1275-1283. 10.1038/mt.2010.79.PubMedPubMedCentral

80.

Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA: Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther. 2000, 11: 2219-2230. 10.1089/104303400750035744.PubMed

81.

McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006, 66: 2509-2513. 10.1158/0008-5472.CAN-05-2242.PubMed

82.

Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60: 2497-2503.PubMed

83.

Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C, Kiyono T, Kikkawa F, Nishiyama Y: Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther. 2011, 18: 77-86. 10.1038/cgt.2010.53.PubMedPubMedCentral

84.

Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther. 2006, 5: 755-766. 10.1158/1535-7163.MCT-05-0334.PubMed

85.

Thorne SH, Contag CH: Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther. 2008, 15: 753-758. 10.1038/gt.2008.42.PubMed

86.

Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW: Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007, 14: 324-333. 10.1038/sj.gt.3302880.PubMed

87.

Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A: Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 2007, 18: 627-641. 10.1089/hum.2007.034.PubMed

88.

Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT: Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007, 105: 157-167. 10.1007/s10549-006-9449-8.PubMed

89.

Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, Rubin SC, Albelda SM, Molnar-Kimber KL: Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res. 1999, 5: 1523-1537.PubMed

90.

Power AT, Bell JC: Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther. 2007, 15: 660-665.PubMed

91.

Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A, Tagawa M: Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther. 2007, 15: 1121-1128.PubMed

92.

Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N, Russell SJ: Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther. 2007, 15: 114-122. 10.1038/sj.mt.6300020.PubMed

93.

Alcayaga-Miranda F, Cascallo M, Rojas JJ, Pastor J, Alemany R: Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Ther. 2010, 17: 792-802. 10.1038/cgt.2010.36.PubMed

94.

MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T: Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One. 2010, 5: e14462-10.1371/journal.pone.0014462.PubMedPubMedCentral

95.

Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR: Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011

96.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD: Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther. 2010, 18: 888-895. 10.1038/mt.2010.44.PubMedPubMedCentral

97.

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M: Targeting tumor vasculature with an oncolytic virus. Mol Ther. 2011, 19: 886-894. 10.1038/mt.2011.26.PubMedPubMedCentral

98.

Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005, 23: 1011-1027.PubMed

99.

Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimaki A: Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol. 2010, 84: 856-866. 10.1128/JVI.00692-09.PubMedPubMedCentral

100.

Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA: Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA. 2009, 106: 12915-12920. 10.1073/pnas.0900660106.PubMedPubMedCentral

101.

Qiu CW, Lin DG, Wang JQ, Li CY, Deng GZ: Expression and significance of PTEN and VEGF in canine mammary gland tumours. Vet Res Commun. 2008, 32: 463-472. 10.1007/s11259-008-9049-7.PubMed

102.

Platt SR, Scase TJ, Adams V, Wieczorek L, Miller J, Adamo F, Long S: Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. J Vet Intern Med. 2006, 20: 663-668. 10.1111/j.1939-1676.2006.tb02912.x.PubMed

103.

Al-Dissi AN, Haines DM, Singh B, Kidney BA: Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas. Can Vet J. 2010, 51: 1109-1114.PubMedPubMedCentral

104.

Mederle O, Mederle N, Bocan EV, Ceausu R, Raica M: VEGF expression in dog mastocytoma. Rev Med Chir Soc Med Nat Iasi. 2010, 114: 185-188.PubMed

105.

Amorim RL, Pinczowski P, Neto RT, Rahal SC: Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours. Vet Comp Oncol. 2010, 8: 23-27. 10.1111/j.1476-5829.2009.00202.x.PubMed

106.

de Queiroz GF, Dagli ML, Fukumasu H, Zavala AA, Matera JM: Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. J Vet Diagn Invest. 2010, 22: 105-108. 10.1177/104063871002200121.PubMed

107.

Blackwood L, O'Shaughnessy PJ, Reid SW, Argyle DJ: E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy. Vet J. 2001, 161: 269-279. 10.1053/tvjl.2000.0557.PubMed

108.

Hlavaty J, Jandl G, Liszt M, Petznek H, Konig-Schuster M, Sedlak J, Egerbacher M, Weissenberger J, Salmons B, Gunzburg WH, Renner M: Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol. 2011, 102: 59-69. 10.1007/s11060-010-0295-5.PubMed

109.

Touchefeu Y, Vassaux G, Harrington KJ: Oncolytic viruses in radiation oncology. Radiother Oncol. 2011, 99: 262-270. 10.1016/j.radonc.2011.05.078.PubMed

110.

Wennier ST, Liu J, McFadden G: Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy. Curr Pharm Biotechnol. 2011

111.

Woo Y, Adusumilli PS, Fong Y: Advances in oncolytic viral therapy. Curr Opin Investig Drugs. 2006, 7: 549-559.PubMed

112.

Vile R, Ando D, Kirn D: The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther. 2002, 9: 1062-1067. 10.1038/sj.cgt.7700548.PubMed

113.

Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF: The dog as a cancer model. Nat Biotechnol. 2006, 24: 1065-1066.PubMed

114.

Vail DM, MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000, 18: 781-792. 10.3109/07357900009012210.PubMed

115.

Hansen K, Khanna C: Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer. 2004, 40: 858-880. 10.1016/j.ejca.2003.11.031.PubMed

116.

Genelhu MC, Cardoso SV, Gobbi H, Cassali GD: A comparative study between mixed-type tumours from human salivary and canine mammary glands. BMC Cancer. 2007, 7: 218-10.1186/1471-2407-7-218.PubMedPubMedCentral

117.

Hayes HM, Fraumeni JF: Epidemiological features of canine renal neoplasms. Cancer Res. 1977, 37: 2553-2556.PubMed

118.

Bukowski JA, Wartenberg D, Goldschmidt M: Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk. J Toxicol Environ Health A. 1998, 54: 579-591. 10.1080/009841098158719.PubMed

119.

Rivera P, von Euler H: Molecular biological aspects on canine and human mammary tumors. Vet Pathol. 2011, 48: 132-146. 10.1177/0300985810387939.PubMed

120.

Wildner O, Hoffmann D, Jogler C, Uberla K: Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther. 2003, 10: 791-802. 10.1038/sj.cgt.7700638.PubMed

121.

Hallden G, Hill R, Wang Y, Anand A, Liu TC, Lemoine NR, Francis J, Hawkins L, Kirn D: Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther. 2003, 8: 412-424. 10.1016/S1525-0016(03)00199-0.PubMed

122.

Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N, Kirn D: E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol. 2003, 21: 1328-1335. 10.1038/nbt887.PubMed

123.

Withrow SJ, Powers BE, Straw RC, Wilkins RM: Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res. 1991, 159-168.

124.

Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC: Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005, 438: 803-819. 10.1038/nature04338.PubMed

Title: Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
Authors: Sandeep S Patil
Ivaylo Gentschev
Ingo Nolte
Gregory Ogilvie
Aladar A Szalay
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-10-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Phenotypes and clinical significance of circulating CD4+CD25+ regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF)

De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer

GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer

Low density lipoprotein receptor-related protein 1 expression correlates with cholesteryl ester accumulation in the myocardium of ischemic cardiomyopathy patients

Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy

NF-κB as potential target in the treatment of melanoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials